SCHEDULE 13G: FMR LLC Discloses 5.2% Stake in Cellebrite DI Ltd.

FMR LLC, the parent company of Fidelity Investments, has disclosed a 5.2% beneficial ownership stake in Cellebrite DI Ltd. as of December 31, 2024, held in the ordinary course of business.

Summary

• FMR LLC, along with its affiliates and Abigail P. Johnson, reported beneficial ownership of 10,621,344 shares of Cellebrite DI Ltd. Common Stock.
• This ownership represents 5.2% of Cellebrite DI Ltd.'s outstanding common stock as of December 31, 2024.
• FMR LLC holds sole voting power and sole dispositive power over all 10,621,344 shares.
• The filing was made under Rule 13d-1(b), indicating that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
• Abigail P. Johnson, as a control person of FMR LLC, is also listed as a reporting person with sole dispositive power over the same number of shares.

Sentiment

Score: 6

Explanation: The disclosure of a significant institutional stake by a reputable asset manager like FMR LLC is generally a positive signal of investor confidence, although the filing itself is a routine compliance document.

Positives

• The disclosure of a significant 5.2% stake by a major institutional investor like FMR LLC (Fidelity) can be viewed as a vote of confidence in Cellebrite DI Ltd.'s long-term prospects.
• The filing explicitly states that the shares are held in the ordinary course of business and not for control purposes, suggesting a passive, investment-oriented holding.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding Cellebrite DI Ltd.'s future performance or strategic direction.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11." (Certification by Stephanie J. Brown on behalf of FMR LLC and Abigail P. Johnson)

Industry Context

This Schedule 13G filing is a routine disclosure of an institutional investor's passive ownership stake and does not provide specific insights into broader industry trends or competitive dynamics for Cellebrite DI Ltd.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, potentially reinforcing confidence in the company.

Key Dates

Keywords

Cellebrite DI Ltd, FMR LLC, Fidelity Investments, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, M2197Q107